$NEOT, 1.44, watch for 1.52 break sends it to 1.88, chart & catalyst:
Plans to begin a new P2 trial during 3Q16 evaluating modified formulation w/ topline data expected during 1Q17. Plans to begin P2 proof of concept trial during 3Q16 to reduce fat deposits under chin (submental fat) w/ topline data expected by YE16, being developed as novel injected formulation of drug approved in several inhaled products (e.g. ADVAIR)